State Street’s INmune Bio INMB Stock Holding History

State Street’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$329K	Sell	290,879 -56,380	-16%	-$80.3K	﹤0.01%	3758
2025 Q4	$542K	Buy	347,259 +63,426	+22%	+$113K	﹤0.01%	3657
2025 Q3	$588K	Buy	283,833 +8,441	+3%	+$19.3K	﹤0.01%	3624
2025 Q2	$636K	Buy	275,392 +39,264	+17%	+$288K	﹤0.01%	3573
2025 Q1	$1.84M	Buy	236,128 +9,700	+4%	+$77K	﹤0.01%	3274
2024 Q4	$1.06M	Hold	226,428	–	–	﹤0.01%	3482
2024 Q3	$1.22M	Buy	226,428 +58,838	+35%	+$418K	﹤0.01%	3451
2024 Q2	$1.48M	Buy	167,590 +122,527	+272%	+$1.21M	﹤0.01%	3412
2024 Q1	$529K	Hold	45,063	–	–	﹤0.01%	3630
2023 Q4	$507K	Buy	45,063 +100	+0.2%	+$838	﹤0.01%	3638
2023 Q3	$308K	Hold	44,963	–	–	﹤0.01%	3805
2023 Q2	$408K	Hold	44,963	–	–	﹤0.01%	3743
2023 Q1	$290K	Hold	44,963	–	–	﹤0.01%	3939
2022 Q4	$285K	Hold	44,963	–	–	﹤0.01%	3968
2022 Q3	$279K	Hold	44,963	–	–	﹤0.01%	3995
2022 Q2	$397K	Buy	44,963 +7,300	+19%	+$54.3K	﹤0.01%	3927
2022 Q1	$317K	Buy	37,663 +3,847	+11%	+$34.5K	﹤0.01%	4222
2021 Q4	$345K	Buy	33,816 +6,100	+22%	+$90.3K	﹤0.01%	4142
2021 Q3	$538K	Sell	27,716 -7,100	-20%	-$137K	﹤0.01%	3942
2021 Q2	$612K	Buy	+34,816	New	+$469K	﹤0.01%	3791

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

State Street's INMB Position: Q1 2026 in Review

State Street reduced its INmune Bio (INMB) stake by 16% in Q1 2026, selling an estimated $80.3K and leaving 290,879 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #3758.

State Street first reported a position in INMB in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.84M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

State Street held 290,879 shares of INmune Bio worth $329K as of Q1 2026.
State Street sold 56,380 INmune Bio shares in Q1 2026, an estimated $80.3K.
INmune Bio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3758 holding.
State Street first reported a position in INmune Bio in Q2 2021 and has held it in 20 quarters since.
State Street's INmune Bio position peaked at $1.84M in Q1 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.